ReachRxResearch
Home
Research
Sign Up
  1. Home
  2. Research Hub
  3. A distinct effector B cell population dr…

A distinct effector B cell population drives autoantibody production in SARS-CoV-2 infection

Immunity·August 28
ImmunologyPractice changingAutoimmune DiseaseCOVID-19Long COVIDObservational Cohort Study With In Vitro ExperimentsB Cell ImmunologyTLR7/8 SignalingMixed

Summary

View source

What was studied

This study investigated the cellular origins of autoantibodies (autoAbs) in SARS-CoV-2 infection using the INCOV cohort (n=12, age- and sex-matched participants with varying autoAb levels), integrating single-cell RNA-seq, ATAC-seq, plasma proteomics, proteome-wide autoAb profiling, and in vitro assays.

Key findings

CD11c+ atypical memory B cells (double-negative 2, DN2s) were identified as key precursors of autoAb-producing cells; autoAb abundance inversely correlated with neutralizing IgG, and in vitro TLR7/8 stimulation preferentially drove atypical memory B cells toward autoAb-secreting differentiation. DN2s showed the strongest enrichment for autoimmune trait heritability among all B cell subsets.

Study limitations

The discovery cohort is very small (n=12), limiting statistical power and generalizability. The study is observational and in vitro findings may not fully reflect in vivo biology. Causal directionality between DN2 expansion and autoAb production cannot be firmly established from this design.

Clinical implications

Clinicians should be aware that autoantibody production in COVID-19 may be driven by a distinct DN2 B cell subset, which could represent a future therapeutic target—particularly for patients at risk of Long COVID or autoimmune sequelae. Monitoring autoAb levels alongside neutralizing IgG may help stratify disease severity risk.

Caveats

  • The sample size of n=12 is very small; findings should be considered exploratory and hypothesis-generating rather than definitive. The impact_flag 'practice_changing' reflects the novelty of mechanistic findings, but clinical translation requires validation in larger cohorts. Study design is labeled 'observational cohort with in vitro experiments' — it does not fit a single canonical study design label cleanly.

Related Questions

Explore related topics

What is the role of atypical memory B cells in autoimmune disease after viral infection?How do autoantibodies contribute to Long COVID severity and mortality?Are TLR7/8 signaling pathways a viable therapeutic target in COVID-19 autoimmunity?

Publication Details

Year
2026
Journal
Immunity
Sample Size
n=12
Source
View article
Keep scrolling
More content below.
Up Next